Kimberly Eyer

This study maps the microbiota composition along the reproductive tract in endometriosis patients, revealing microbial dysbiosis, reduced Lactobacillus, and increased Pseudomonas and Sphingobium in upper reproductive sites. These findings suggest potential microbial contributions to inflammation, lesion persistence, and new biomarkers for diagnosing endometriosis.

Graves’ disease patients display a distinct gut microbiota signature, characterized by reduced diversity and altered abundance of key microbial taxa, including increased Bacilli, Prevotella, and Megamonas, and decreased Ruminococcus and Alistipes, suggesting a role for the microbiome in GD pathogenesis.

Graves’ disease patients show distinctive gut microbiota profiles, with increased Bacteroidetes and specific pro-inflammatory bacteria, despite no difference in overall diversity. Key taxa correlate with clinical GD parameters, highlighting their potential as diagnostic biomarkers and supporting a role for gut dysbiosis in GD pathogenesis.

This cross-sectional study found that Graves’ disease patients have distinctly altered gut microbiota—lower Firmicutes, higher Bacteroidetes, and reduced butyrate-producers—suggesting a role for the microbiome in disease pathogenesis and as a diagnostic biomarker.

This study demonstrates that Graves’ disease and Hashimoto’s thyroiditis patients share distinct gut microbiome signatures—particularly involving Bacillus, Blautia, and Ornithinimicrobium—and a common enrichment of the ABC transporter pathway, supporting a microbiome-driven mechanism in autoimmune thyroid disease pathogenesis.

This study identified distinct alterations in gut microbiota composition and function in Graves’ disease and Graves’ orbitopathy patients compared to healthy controls, highlighting specific microbial taxa and metabolic pathways that may contribute to disease mechanisms and serve as future biomarkers.

Integrated microbiome-metabolome study reveals dysbiosis and metabolic shifts in Graves’ disease and hypothyroidism, highlighting potential biomarkers like depleted Bacteroides for thyroid disorders.

This study reveals that Graves’ disease patients exhibit distinct gut microbiota signatures, with increased Bacteroidetes and Prevotellaceae and decreased Firmicutes and Lachnospiraceae, strongly associated with thyroid function markers. These microbial shifts may play a role in GD pathogenesis and serve as potential clinical biomarkers.

This study identified distinctive alterations in gut microbiota in Graves’ disease, including reduced diversity and specific taxonomic shifts. Key microbial signatures correlated with thyroid autoimmunity, highlighting potential diagnostic biomarkers and suggesting that microbiome modulation may offer new therapeutic avenues for Graves’ disease.

This study demonstrates that gut microbiome composition and function differ significantly between Graves’ disease and Graves’ orbitopathy, with specific taxa correlating with thyroid autoimmunity. These findings highlight the potential of gut microbial markers for distinguishing GO from GD and understanding disease mechanisms.

Erectile dysfunction (ED) involves the consistent inability to sustain an erection, frequently connected to broader health issues and disturbances in the gut microbiome.

This study found that gut microbiota in Hashimoto’s thyroiditis patients differs markedly from healthy controls, with enriched Escherichia coli and depleted Prevotella. These microbial shifts support the hypothesis that dysbiosis contributes to autoimmune thyroid inflammation and may offer targets for intervention.

Oral microbiota in new-onset rheumatoid arthritis shows unique enrichment of Prevotella, Leptotrichia, and Anaeroglobus, independent of periodontitis severity. These taxa may act as microbial triggers or biomarkers for autoimmunity, suggesting the oral microbiome’s relevance in RA onset and potential for diagnostic or therapeutic targeting.

This study shows that the oral microbiota in early rheumatoid arthritis includes enriched Tannerella forsythia and Streptococcus anginosus, correlating with increased periodontal attachment loss. These findings suggest early microbial dysbiosis may influence RA pathogenesis and serve as diagnostic biomarkers or targets for preventive care.

This study identifies oral microbiome biomarkers for arthritis screening, distinguishing RA from OA using salivary microbial profiles. It highlights Prevotella and Veillonella in RA and Rothia and Streptococcus in OA, supporting microbiome-based diagnostics.

Subgingival microbiome in rheumatoid arthritis reveals microbial community shifts driven by disease activity, smoking, and treatment. Prednisolone use correlates with healthier profiles, while smoking promotes dysbiosis, highlighting microbial biomarkers for RA management.

This study reveals that gut microbiota dysbiosis in immune-mediated inflammatory diseases includes shared enrichment of pro-inflammatory taxa like Streptococcus and Eggerthella, alongside depletion of beneficial genera such as Roseburia. These patterns support a common microbial signature across IMIDs and highlight potential targets for diagnosis and therapeutic intervention.

This study on the subgingival microbiome in rheumatoid arthritis and periodontitis identified Treponema enrichment in RA. Despite similar microbial richness across groups, specific dysbiotic shifts suggest that oral bacteria, particularly Treponema and Porphyromonas, may bridge periodontal and systemic inflammation in RA pathogenesis.

This study used gut microbiome metagenomics in rheumatoid arthritis to identify Prevotella enrichment and redox gene loss in RA. Findings reveal microbiome-host genomic interactions and metabolic shifts that define RA pathogenesis, offering population-specific microbial signatures and potential therapeutic targets based on microbial function and immunogenetic alignment.

This study found that oral microbiota in early rheumatoid arthritis displays distinct bacterial enrichments and metabolic shifts. Key taxa, including Filifactor alocis and Porphyromonas endodontalis, were elevated in RA regardless of periodontal status, highlighting their potential as biomarkers and microbial contributors to RA pathogenesis.

This study links the subgingival microbiome in rheumatoid arthritis to elevated ACPAs via enrichment of A. butyrica, P. simiae, and P. stomatis. These bacteria contribute to citrullination and may be key microbial biomarkers or MBTI targets in RA-associated periodontitis.

This study reveals that intrauterine microbial colonization is prevalent in women with endometriosis, particularly with Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. Findings suggest that GnRHa treatment exacerbates microbial colonization, indicating a possible role for targeted antimicrobial therapies in managing endometriosis-associated inflammation.

This study found that endometriosis does not induce significant changes in the fecal bacteriota composition during the acute phase of lesion formation. Findings suggest that gut microbial shifts in endometriosis may emerge only during chronic disease stages, highlighting the need for targeted microbiome interventions over prolonged periods.

This study shows that antibiotic therapy with metronidazole reduces endometriotic lesion growth and inflammation in mice by targeting the gut microbiota, particularly Bacteroidetes. Findings suggest that microbiota-targeted treatments may offer new therapeutic avenues for endometriosis management.